Mydecine Innovations Net Income vs. Current Ratio
| MYCOF Stock | USD 0 0 44.00% |
For Mydecine Innovations profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Mydecine Innovations to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Mydecine Innovations Group utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Mydecine Innovations's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Mydecine Innovations Group over time as well as its relative position and ranking within its peers.
Mydecine |
Mydecine Innovations Current Ratio vs. Net Income Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Mydecine Innovations's current stock value. Our valuation model uses many indicators to compare Mydecine Innovations value to that of its competitors to determine the firm's financial worth. Mydecine Innovations Group is considered to be number one stock in net income category among its peers. It also is considered to be number one stock in current ratio category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Mydecine Innovations' earnings, one of the primary drivers of an investment's value.Mydecine Current Ratio vs. Net Income
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Mydecine Innovations |
| = | (28.9 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Mydecine Innovations |
| = | 1.26 X |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Mydecine Current Ratio Comparison
Mydecine Innovations is currently under evaluation in current ratio category among its peers.
Mydecine Innovations Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Mydecine Innovations, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Mydecine Innovations will eventually generate negative long term returns. The profitability progress is the general direction of Mydecine Innovations' change in net profit over the period of time. It can combine multiple indicators of Mydecine Innovations, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Mydecine Innovations Group Inc., a biotech and life sciences company, engages in the development and commercialization of drugs for treating mental health problems. Mydecine Innovations Group Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada. Mydecine Innovations operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 11 people.
Mydecine Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Mydecine Innovations. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Mydecine Innovations position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Mydecine Innovations' important profitability drivers and their relationship over time.
Use Mydecine Innovations in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mydecine Innovations position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mydecine Innovations will appreciate offsetting losses from the drop in the long position's value.Mydecine Innovations Pair Trading
Mydecine Innovations Group Pair Trading Analysis
The ability to find closely correlated positions to Mydecine Innovations could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mydecine Innovations when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mydecine Innovations - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mydecine Innovations Group to buy it.
The correlation of Mydecine Innovations is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mydecine Innovations moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mydecine Innovations moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Mydecine Innovations can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Mydecine Innovations position
In addition to having Mydecine Innovations in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Small & Mid Caps ETFs Thematic Idea Now
Small & Mid Caps ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Small & Mid Caps ETFs theme has 19 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Small & Mid Caps ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Mydecine Pink Sheet
To fully project Mydecine Innovations' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Mydecine Innovations at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Mydecine Innovations' income statement, its balance sheet, and the statement of cash flows.